Inflammatory Disease Markers Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Summary
GlobalData's Medical Devices sector report, “Inflammatory Disease Markers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Inflammatory Disease Markers pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Inflammatory Disease Markers are antigen/antibodies that detect specific antigen/antibodies produced by bone, cartilage or any other inflammatory disease activity.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Inflammatory Disease Markers under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Inflammatory Disease Markers and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Inflammatory Disease Markers under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
About GlobalData
Introduction
Inflammatory Disease Markers Overview
Products under Development
Inflammatory Disease Markers - Pipeline Products by Stage of Development
Table Figure 1: Inflammatory Disease Markers - Pipeline Products by Stage of Development
Table Inflammatory Disease Markers - Pipeline Products by Stage of Development
Inflammatory Disease Markers - Pipeline Products by Segment
University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview
Table University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview
Table Blood-Based Diagnostic Test - Endometriosis - Product Status
Table Blood-Based Diagnostic Test - Endometriosis - Product Description
University of Oxford Company Overview
University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
Table University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
Table Biomarker Based Assay - Rheumatoid Arthritis - Product Status
Table Biomarker Based Assay - Rheumatoid Arthritis - Product Description
University of Rochester Company Overview
University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
Table University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
Table PBMC-Based Companion Diagnostic Test - Product Status
Table PBMC-Based Companion Diagnostic Test - Product Description
University of Warwick Company Overview
University of Warwick Pipeline Products & Ongoing Clinical Trials Overview
Table University of Warwick Pipeline Products & Ongoing Clinical Trials Overview
Table Diagnostic Test - Arthritis - Product Status
Table Diagnostic Test - Arthritis - Product Description
University Rovira i Virgili Company Overview
University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview
Table University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview
Table CD-Medics Test - RA - Product Status
Table CD-Medics Test - RA - Product Description
Inflammatory Disease Markers- Recent Developments
Aug 28, 2023: Bio-Rad to Participate in Fireside Chat During Wells Fargo's 2023 Healthcare Conference
Aug 24, 2023: LumiraDx Reports Second Quarter 2023 Results
Aug 17, 2023: Myriad Genetics to Host Investor Day on September 19, 2023
Aug 16, 2023: LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
Aug 14, 2023: Thermo Fisher Scientific to Trim Staff by More Than 200 at Florida Site
Jul 17, 2023: Theradiag Reports Revenue of €6.7 Million for the First Half of 2023, up 6.8%
Jul 05, 2023: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 26, 2023
Jun 15, 2023: Arvinas Announces Changes to its Board of Directors
Jun 05, 2023: StageZero Life Sciences Announces Special and Annual General Meeting Conference Call
May 30, 2023: SQI Diagnostics reports second quarter 2023 results
May 10, 2023: VolitionRx announces first quarter 2023 financial results and business update
May 09, 2023: LumiraDx to announce first quarter financial results and host quarterly conference call on May 16
May 05, 2023: VolitionRx schedules first quarter 2023 earnings conference call and business update
May 03, 2023: Myriad Genetics reports first quarter 2023 financial results
May 01, 2023: Brand new LifeLabs Patient Service Centre opens in Komoka, Ontario
Mar 31, 2023: StageZero Life Sciences Announces Q4 2022 and Year End Financial Results and Operational Update
Mar 30, 2023: StageZero to Issue Q4 2022 Financial Results on Friday March 31
Mar 29, 2023: StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30
Mar 28, 2023: EKF Diagnostics Holdings Announces its final results for the year ended 31 December 2022
Mar 15, 2023: VolitionRx Announces Full Fiscal Year 2022 Financial Results and Business Update
Mar 14, 2023: LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
Mar 10, 2023: VolitionRx Schedules Full Year 2022 Earnings Conference Call and Business Update
Mar 08, 2023: Otsuka Pharmaceutical Announces Appointments of Board Members and Statutory Auditors
Mar 06, 2023: VolitionRx to Webcast Live at VirtualInvestorConferences.com March 9th
Jan 16, 2023: TheraDiag Reports 2022 Revenue of €12.2 Million, up 9.7%
Jan 09, 2023: NIH funds eight studies to advance rapid diagnosis of COVID-19-related inflammatory syndrome in children
Jan 06, 2023: Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
Jan 03, 2023: Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio
Dec 19, 2022: Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
Nov 21, 2022: Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference
Nov 15, 2022: StageZero Life Sciences Announces Q3 2022 Financial Results and Operational Update
Nov 11, 2022: StageZero to Hold Q3 2022 Operational and Financial Results Conference Call on Tuesday November 15, 2022
Nov 09, 2022: VolitionRx Limited Schedules Third Quarter 2022 Earnings Conference Call and Business Update
Nov 02, 2022: LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
Oct 31, 2022: Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
Oct 31, 2022: Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
Oct 27, 2022: Bio-Rad Reports Third-Quarter 2022 Financial Results
Oct 17, 2022: Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
Sep 30, 2022: Theradiag: Appointment of an Independent Expert
Sep 19, 2022: Theradiag Announces Its Results for the First Half of 2022: Breaking-Even and Confirming Its Ability to Be Structurally Profitable From Early 2023